Covance Inc.
announced that the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) awarded full accreditation to the company's early development research facility in Shanghai, China. Promoting the humane treatment of animals in science worldwide through voluntary accreditation and assessment programs, AAALAC International recognizes the highest standards for animal care and use in 34 countries.
"Covance takes very seriously our obligations to the animals in our care. The unanimous approval from AAALAC International for full accreditation with no additional recommendations for improvement affirms that we adhere to the highest standards of animal care," said Honggang Bi, Corporate Vice President and General Manager, Covance China. "The Council on Accreditation of AAALAC International commended the management and staff at the Shanghai facility for providing institutional and administrative commitment to the animal care program as evidenced by our newest facility, equipment, and programs."
Covance’s facility in Shanghai provides bioanalytical, toxicology, lead optimization toxicology, in-vivo PK screening, and metabolism services. Covance continues to invest in China to offer its clients a growing range of preclinical safety assessment services to help pharmaceutical and biotechnology companies achieve study goals quickly and with greater confidence.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.